Cihan Ay "Cancer and VTE: mechanistic underpinnings of risk"
Cancer is a strong and independent risk factor for thrombosis. The epidemiology, risk factors and molecular mechanisms of cancer-associated thrombosis (CAT) differ from venous thromboembolism in the general population.
Marc Carrier "Medical treatment of cancer-associated VTE in 2018"
Recent clinical trials have assessed the role of direct oral anticoagulants (DOACs) for the management of cancer-associated thrombosis (CAT).
Supported by an unrestricted educational grant from: Bayer
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.
The ISTH webinar series will provide high quality and state of the art education to practitioners around the world. Throughout the course of the year, the series will provide both clinical and basic science education in the areas of Thrombosis and Anticoagulation; Platelets and Vascular Biology; Coagulation and Bleeding Disorders.
- Review the epidemiology of CAT.
- Understand the risk factors and discuss clinical prediction models for CAT.
- Summarize recent advances in understanding the mechanisms of CAT.
- Review the evidence for the acute treatment of CAT and discuss the role of DOACs
- Discuss the clinical characteristics to consider in tailoring anticoagulation management for the treatment of CAT.
All persons in control of content have NO relevant financial relationships to disclose with the exception of the following persons:
|Geoffrey Barnes, MD, MSc||BMS/Pfizer, NHLBI, Blue Cross Blue Shield of Michigan, Portola Janssen||Research Investigator, Consultant|
|Meera Chitlur, MD||Bayer, Genentech, Novo nardisk, Baxter||Advisory Board, Consultant, Speaker|
|Marc Carrier||Canadian Institute of Health Research, Pfizer, Sanofi, LEO Pharma, Bristol-Myers Squibb, Bayer, Octapharma, Sanofi, Boehringer Ingelheim|
Grant Review Committee, Advisory Board, PI, Speaker
|Tzu-Fei Wang||Daiichi Sankyo, Pfizer/BMS||Consultant, Advisory Board|
|Cihan Ay||Bayer, Daiichi-Sankyo||Speaker, Advisory Board|
Cihan Ay is currently an associate professor in medicine/haemostaseology at the Medical University of Vienna, Austria, and has been a visiting research professor at the University of North Carolina at Chapel Hill, NC, USA (2016-2017).
He serves as co-director of the program for inherited bleeding disorders and acquired thrombophilia at the Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna – Vienna General Hospital, Austria.
He studied medicine at the Medical University of Vienna, Austria and the Ruprecht-Karls-University in Heidelberg, Germany. In 2006, he graduated from the Medical University of Vienna, Austria and received there his medical training and completed specialisation in internal medicine, haematology and medical oncology.
His research and clinical work focuses on venous thromboembolism (VTE), anticoagulation and bleeding disorders. He has authored over 130 peer-reviewed publications in the field of thrombosis and haemostasis, and his work has contributed particularly to a better understanding of the etiology of VTE in cancer by identifying biomarkers and clinical risk factors for cancer-associated VTE.
He is an active peer reviewer for major medical journals in the field including the BMJ, Circulation, Blood, ATVB, Haematologica, Journal of Thrombosis and Haemostasis (JTH), Thrombosis Research and Thrombosis & Haemostasis (T&H), etc.
He also serves as Co-Chair of the Scientific and Standardization Committee (SSC) Subcommittee of the International Society on Thrombosis and Haemostasis (ISTH) on Haemostasis and Malignancy, on the Editorial Board of JTH and Thrombosis Research, and as an associate editor of Research and Practice in Thrombosis and Haemostasis (RPTH), the new open access journal of ISTH.
Cihan Ay is a passionate clinician and researcher, and supervisor of diploma and PhD-students. Further, he has been engaged in regular teaching activities for health care professionals to provide education in the field of thrombosis, haemostasis and anticoagulation.
Dr. Marc Carrier, M.D., MSc, FRCPC, is an Associate Professor in the Faculty of Medicine, Department of Medicine and Senior Scientist in the Clinical Epidemiology Program of The Ottawa Hospital Research Institute. He holds a Tier 2 Research Chair in Venous Thromboembolism and Cancer from the University of Ottawa and a New Investigator Award from the Heart and Stroke Foundation of Canada.
His clinical research is focused in venous thromboembolic disease and cancer, including cancer screening, prevention and management. He is currently the Principal Investigator on four peer-reviewed clinical trials (Heart and Stroke Foundation (2) and Canadian Institute of Health Research (2) ) and numerous industry sponsored trials. Has published important systematic reviews and has had multiple international speaking invitations to speak on the topics of cancer and thrombosis.
Dr. Carrier is currently the Chairman of the SSC Subcommittee on Hemostasis and Malignancy and was elected as the SSC Chairman-Elect in 2018, his term as Chairman-elect will begin in July 2018.
Dr. Tzu-Fei Wang is an Assistant Professor of Medicine, The Ohio State University. Dr. Wang’s research interests include the investigation of optimal prevention and treatment strategies for venous thromboembolism in various population, including cancer patients. Dr. Wang is a member of the International Society of Thrombosis and Haemostasis Hemostasis and Malignancy subcommittee, the National Comprehensive Cancer Network’s Cancer-Associated Thromboembolic Disease Panel and a member of the US thrombosis network, VENUS consortium.